Is AC Immune SA halal to invest in?

According to Musaffa's Shariah screening methodology, AC Immune SA (ACIU) is currently classified as NOT HALAL as of March 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is AC Immune SA a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes AC Immune SA using these criteria to determine its compliance status.

Can Muslims buy shares of AC Immune SA?

Muslim investors may consider investing in AC Immune SA if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is AC Immune SA classified as NOT HALAL?

Musaffa determines the Shariah status of AC Immune SA by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for AC Immune SA updated?

The Shariah compliance status of AC Immune SA may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like AC Immune SA become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of AC Immune SA?

You can check the latest Shariah compliance status of AC Immune SA on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

ACIU Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: March 30, 2026

Report Source: 2025 Annual Report

AC Immune SA. Stock Analysis ACIU

United States Health Care Small Cap Report: 2025 Annual

AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. The firm focuses on precision medicine for neurodegenerative diseases. The company designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The firm's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. The company has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.

Key Statistics of AC Immune SA (ACIU)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$2.73$2.84

Today's Open

$2.84

Volume

357.19K

P/E Ratio (TTM)

52 Week Range

$1.52$4.00

Market Cap

306.34M

Avg. Volume

276.43K

Dividend Yield

Financial Metrics & Statements of AC Immune SA (ACIU)

FAQ's for AC Immune SA (ACIU)

According to Musaffa’s Shariah screening methodology, AC Immune SA (ACIU) is currently classified as NOT HALAL as of March 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.